Asimadoline Positive Results In Irritable Bowel Syndrome Trial

Armen Hareyan's picture
Advertisement

Tioga Pharmaceuticals announced the results of a recent Phase 2b study of its oral kappa opioid receptor agonist, asimadoline, which demonstrated statistically significant results in the treatment of Irritable Bowel Syndrome (IBS). Asimadoline produced significant improvement in diarrhea-predominant (D-IBS) and alternating (A-IBS) patients across multiple parameters including the primary endpoint of pain, as well as secondary endpoints of urgency, frequency and bloating in both males and females. In D-IBS patients, therapeutic benefit was observed within the first month of treatment and was sustained for the three month duration of the trial. Asimadoline appeared to be well tolerated with no adverse events occurring in a dose-dependent manner throughout the randomized, double-blind, placebo-controlled, dose-ranging clinical trial involving 596 subjects. These data were featured today in a late-breaking oral presentation session at the Digestive Disease Week 2008 Annual Meeting.

Advertisement